Precondensed Plasmid DNA enhances CAR-T cell generation via lipid nanoparticles
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The advent of chimeric antigen receptor (CAR) T-cell therapy has introduced a novel and personalized approach to cancer treatment. Despite its promise, the challenge of developing a system that bypasses the need for viral vectors remains significant, particularly in terms of achieving a clinical efficacy and sustained durability. To address these challenges, lipid nanoparticles (LNPs) produced through advanced microfluidic technology have been recently utilized to encapsulate plasmid DNA (pDNA) encoding CAR receptors. However, the intrinsic challenges associated with pDNA encapsulation, along with the critical requirement for efficient expression, remain substantial obstacles. Here, we show that incorporating DNA-condensing agents into the microfluidic manufacturing of LNPs effectively overcomes these limitations. Briefly, we conducted a preliminary investigation to characterize LNPs with and without the commercial condensing agent P3000-Reagent (PR), focusing on their physicochemical properties and scrutinizing the biological outcomes primarily in the HEK-293 cell line. Our results demonstrated that precondensation of the pDNA with PR differentially increased the transfection efficiency of the tested formulations, whereas confocal microscopy indicated reduced lysosomal colocalization and major nuclear localization. Finally, PR was found to enhance LNP efficiency upon multiple administrations to the immortalized T-lymphocyte Jurkat cell line, enabling the delivery of both a luciferase reporter gene and a functional CAR-encoding plasmid. Overall, these findings underscore the great potential of introducing DNA-condensing agents into the LNP preparation process, especially for systems designed for challenging delivery applications, such as multiadministration transfection protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DOTAP provides a permanent positive charge that significantly improves transfection in hard-to-transfect cell types.59,60,61”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Schlich, M., Palomba, R., Costabile, G., Mizrahy, S., Pannuzzo, M., Peer, D., & Decuzzi, P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10213 · Cited by 387
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
Caracciolo, G., Pozzi, D., Caminiti, R., Marchini, C., Montani, M., Amici, A., & Amenitsch, H. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp803077n · Cited by 46
Self-citation
Research works printed but not linked: 42
- June, 2018, Chimeric Antigen Receptor Therapy, N. Engl. J. Med., 379, 64, 10.1056/NEJMra1706169 · DOI · Paper page
- Butt, 2022, Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review, Genes, 13, 1370, 10.3390/genes13081370 · DOI · Paper page
- van der Loo, 2016, Progress and challenges in viral vector manufacturing, Hum. Mol. Genet., 25, R42, 10.1093/hmg/ddv451 · DOI · Paper page
- Quagliarini, 2021, Microfluidic formulation of DNA-loaded multicomponent lipid nanoparticles for gene delivery, Pharmaceutics, 13, 1292, 10.3390/pharmaceutics13081292 · DOI
- Samaridou, 2020, Lipid nanoparticles for nucleic acid delivery: Current perspectives, Adv. Drug Deliv. Rev., 154, 37, 10.1016/j.addr.2020.06.002 · DOI · Paper page
- Krammer, 2020, SARS-CoV-2 vaccines in development, Nature, 586, 516, 10.1038/s41586-020-2798-3 · DOI · Paper page
- Quagliarini, 2022, Mechanistic Insights into the Superior DNA Delivery Efficiency of Multicomponent Lipid Nanoparticles: An In Vitro and In Vivo Study, ACS Appl. Mater. Interfaces, 14, 56666, 10.1021/acsami.2c20019 · DOI
- Cui, 2022, Efficient delivery of DNA using lipid nanoparticles, Pharmaceutics, 14, 1698, 10.3390/pharmaceutics14081698 · DOI
- Van de Vyver, 2022, Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics, Adv. Drug Delivery Rev., 181, 114041, 10.1016/j.addr.2021.114041 · DOI
- Giulimondi, 2024, Optimizing Transfection Efficiency in CAR-T Cell Manufacturing through Multiple Administrations of Lipid-Based Nanoparticles, ACS Appl. Bio Mater., 7, 3746, 10.1021/acsabm.4c00103 · DOI
- Martins, 2004, Nuclear Matrix Interactions at the Human Protamine Domain: A Working Model of Potentiation, J. Biol. Chem., 279, 51862, 10.1074/jbc.M409415200 · DOI
- Cornetta, 1989, Protamine sulfate as an effective alternative to Polybrene in retroviral-mediated gene-transfer: implications for human gene therapy, J. Virol. Methods, 23, 187, 10.1016/0166-0934(89)90132-8 · DOI
- Caracciolo, 2011, Factors Determining the Superior Performance of Lipid/DNA/Protammine Nanoparticles over Lipoplexes, J. Med. Chem., 54, 4160, 10.1021/jm200237p · DOI
- Wang, 2018, Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides, Molecules, 23, 2564, 10.3390/molecules23102564 · DOI · Paper page
- Nakamura, 2022, Importance of Process Parameters Influencing the Mean Diameters of siRNA-Containing Lipid Nanoparticles (LNPs) on the in Vitro Activity of Prepared LNPs, Biol. Pharm. Bull., 45, 497, 10.1248/bpb.b21-01016 · DOI
- Engin, 2017, Mechanistic understanding of nanoparticles’ interactions with extracellular matrix: the cell and immune system, Part. Fibre Toxicol., 14, 22, 10.1186/s12989-017-0199-z · DOI · Paper page
- Gilbert, 2024, Evolution of the structure of lipid nanoparticles for nucleic acid delivery: From in situ studies of formulation to colloidal stability, J. Colloid Interface Sci., 660, 66, 10.1016/j.jcis.2023.12.165 · DOI
- Marchini, 2010, Tailoring lipoplex composition to the lipid composition of plasma membrane: a Trojan horse for cell entry?, Langmuir, 26, 13867, 10.1021/la1023899 · DOI
- Warga, 2023, Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA, Mol. Ther. Nucleic Acids, 31, 43, 10.1016/j.omtn.2022.11.025 · DOI
- Tan, 2021, HEK293 cell line as a platform to produce recombinant proteins and viral vectors, Front. Bioeng. Biotechnol., 9, 796991, 10.3389/fbioe.2021.796991 · DOI · Paper page
- Dekevic, 2022, Statistical experimental designs to optimize the transient transfection of HEK 293T cells and determine a transfer criterion from adherent cells to larger-scale cell suspension cultures, J. Biotechnol., 346, 23, 10.1016/j.jbiotec.2022.01.004 · DOI
- Gilleron, 2013, Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape, Nat. Biotechnol., 31, 638, 10.1038/nbt.2612 · DOI · Paper page
- Sfera, 2022, Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics, Front. Pharmacol., 13, 995481, 10.3389/fphar.2022.995481 · DOI
- Rennick, 2021, Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics, Nat. Nanotechnol., 16, 266, 10.1038/s41565-021-00858-8 · DOI · Paper page
- Montani, 2015, Getting the most from gene delivery by repeated DNA transfections, Appl. Phys. Lett., 106, 233701, 10.1063/1.4922288 · DOI
- Abraham, 2004, Jurkat T cells and development of the T-cell receptor signalling paradigm, Nat. Rev. Immunol., 4, 301, 10.1038/nri1330 · DOI · Paper page
- Bloemberg, 2020, A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells, Mol. Ther.--Methods Clin. Dev., 16, 238, 10.1016/j.omtm.2020.01.012 · DOI
- Irvine, 2020, Enhancing cancer immunotherapy with nanomedicine, Nat. Rev. Immunol., 20, 321, 10.1038/s41577-019-0269-6 · DOI · Paper page
- Billingsley, 2020, Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering, Nano Lett., 20, 1578, 10.1021/acs.nanolett.9b04246 · DOI · Paper page
- Billingsley, 2022, Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells, Nano Lett., 22, 533, 10.1021/acs.nanolett.1c02503 · DOI · Paper page
- Prazeres, 2023, Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells, Int. J. Nanomed., 18, 5891, 10.2147/ijn.s424723 · DOI
- Sun, 2023, Structure and function of cationic and ionizable lipids for nucleic acid delivery, Pharm. Res., 40, 27, 10.1007/s11095-022-03460-2 · DOI · Paper page
- Cárdenas, 2023, Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery, Curr. Opin. Colloid Interface Sci., 66, 101705, 10.1016/j.cocis.2023.101705 · DOI · Paper page
- Felgner, 1987, Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. U.S.A., 84, 7413, 10.1073/pnas.84.21.7413 · DOI · Paper page
- Pozzi, 2012, Transfection efficiency boost of cholesterol-containing lipoplexes, Biochim. Biophys. Acta, Biomembr., 1818, 2335, 10.1016/j.bbamem.2012.05.017 · DOI
- Hosseini, 2019, Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR–Cas9, Int. J. Nanomed., 14, 4353, 10.2147/ijn.s199104 · DOI
- Weigel, 1981, Temperature dependence of endocytosis mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. Evidence for two potentially rate-limiting steps, J. Biol. Chem., 256, 2615, 10.1016/S0021-9258(19)69656-0 · DOI · Paper page
- Cardarelli, 2016, The intracellular trafficking mechanism of Lipofectamine-based transfection reagents and its implication for gene delivery, Sci. Rep., 6, 25879, 10.1038/srep25879 · DOI · Paper page
- Chatterjee, 2024, Endosomal escape: A bottleneck for LNP-mediated therapeutics, Proc. Natl. Acad. Sci. U.S.A., 121, 10.1073/pnas.2307800120 · DOI · Paper page
- Zhao, 2012, Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex, J. Contr. Release, 159, 104, 10.1016/j.jconrel.2012.01.007 · DOI · Paper page
- Carrasco-Padilla, 2023, T cell activation and effector function in the human Jurkat T cell model, Methods Cell Biol., 178, 25, 10.1016/bs.mcb.2022.09.012 · DOI
- Caruso, 2019, Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function, J. Neuro Oncol., 145, 429, 10.1007/s11060-019-03311-y · DOI
Cited by
Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.103081
Metadata
- Authors
- Pirrottina, A., Renzi, S., Digiacomo, L., Giulimondi, F., De Lorenzi, V., Ghignoli, S., Pesce, L., Cardarelli, F., Mura, F., Parisi, G., Buccini, L., Cassone, C., Zingoni, A., Pozzi, D., & Caracciolo, G.
- Affiliations
- Sapienza University of Rome , , ,
- Scuola Normale Superiore , , ,
- Venue
- ACS Omega
- Publisher
- American Chemical Society (ACS)
- Published
- 2025-07-04
- Volume
- 10
- Issue
- 27
- Pages
- 29804-29814
- ISSN
- 2470-1343
- Cited by
- 4
- References
- 5
- Language
- en
- Funders
- Ministero dell'Universit? e della Ricerca (CUP: B53C22004000006, PNRR - ECS00000017, PNRR - M4C2I1.3, PNRR - PE_00000019, PON TITAN 2014-2020)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.